<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02107365</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS HC32 QUATTRO</org_study_id>
    <nct_id>NCT02107365</nct_id>
  </id_info>
  <brief_title>Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)</brief_title>
  <official_title>Pilot Study to Assess Efficacy and Safety of a Quadruple Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Non-responders to Pegylated Interferon-Ribavirin Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ANRS, Emerging Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ANRS, Emerging Infectious Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Success rates, after retreatment with Peg-Interferon/Ribavirin bitherapy, in patients&#xD;
      infected with HCV (hepatitis C virus) genotype 4 and non-responders to a first standard&#xD;
      treatment, are disappointing. The association of Asunaprevir and Daclatasvir in combination&#xD;
      with the standard-of-care bitherapy has been shown to increase the efficacy of the treatment&#xD;
      in non-responders genotype 1-infected patients.&#xD;
&#xD;
      Given the absence of current solutions and urgent therapeutic needs for HCV genotype&#xD;
      4-infected patients previously treated with pegylated Interferon/Ribavirin, this pilot study&#xD;
      aims to evaluate the efficacy and safety of a quadritherapy associating Asunaprevir,&#xD;
      Daclatasvir, pegylated Interferon alpha-2a and Ribavirin, in this very difficult to treat&#xD;
      population.&#xD;
&#xD;
      60 subjects will be enrolled.&#xD;
&#xD;
      The primary endpoint will be the rate of sustained virological response (SVR), defined by an&#xD;
      undetectable HCV RNA, at Week 36 (12 weeks after the end of a 24 weeks quadritherapy).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The population studied presents the maximum of factors of non-response to the retreatment of&#xD;
      hepatitis C: non-response to well followed prior treatment with pegylated Interferon and&#xD;
      Ribavirin, infection with HCV genotype 4, and the presence of cirrhosis (in less than 50% of&#xD;
      the included patients) that could diminish the chances of SVR to a standard bitherapy.&#xD;
&#xD;
      The likelihood of SVR with standard bitherapy in this study population is thus considered&#xD;
      low, around 15%.&#xD;
&#xD;
      The principal objective of this multicentric, national, single-arm, open-labeled,&#xD;
      non-randomized phase II pilot study in 60 patients, is to assess the rate of SVR 12 weeks&#xD;
      after 24 weeks of quadritherapy and to determine whether this rate is significantly greater&#xD;
      than 20%.&#xD;
&#xD;
      The proportion of patients presenting with cirrhosis (defined by a METAVIR F4 score on liver&#xD;
      biopsy or with hepatic impulse elastometry ≥ 15 kPa) will be limited to 50% of all patients&#xD;
      included.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SVR12 Rate</measure>
    <time_frame>Week 36</time_frame>
    <description>HCV RNA measured 12 weeks after the end of the HCV treatment (Week 36)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Up to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment discontinuations</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Number and causes of treatment discontinuations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-reported symptoms</measure>
    <time_frame>Day 0, Week 12, Week 36</time_frame>
    <description>ANRS AC24 perceived symptoms scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' adherence</measure>
    <time_frame>Week 4, Week 12, Week 24</time_frame>
    <description>ANRS questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVR 24 rate</measure>
    <time_frame>Week 48</time_frame>
    <description>Undetectable HCV RNA 24 weeks after the end of the HCV treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV viral load</measure>
    <time_frame>Day 0, Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 36, 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with virological failure under treatment</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Patients with detectable HCV viral load at Week 8, or Patients with HCV breakthrough : a) undetectable HCV viral load at Week 8 and detectable at any visit after Week 8 or b) undetectable HCV viral load at any time point before Week 8 and who presents a new confirmed detectable viral load before Week 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV subtypic distribution</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with resistance mutations to Asunaprevir and/or Daclatasvir in case of virological failure</measure>
    <time_frame>Up to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cirrhosis evaluation</measure>
    <time_frame>Baseline, Week 12, Week 24, Week 36, Week 48</time_frame>
    <description>For cirrhotic patients : Child-Pugh and MELD scores ; cirrhosis decompensation evaluation on clinical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance : HOMA-IR score</measure>
    <time_frame>Day 0, Week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic syndrome parameters</measure>
    <time_frame>Day 0, Week 36</time_frame>
    <description>Waist circumference, blood pressure, fasting glucose, triglycerides, HDL cholesterol (composite measure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver fibrosis</measure>
    <time_frame>Between baseline and Week 48</time_frame>
    <description>Evolution of liver fibrosis on biological parameters (Fibrotest®) and imaging (Fibroscan®)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polymorphism of the gene of IL28B</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hepatitis C Virus Genotype 4 Infection</condition>
  <arm_group>
    <arm_group_label>Asunaprevir, Daclatasvir, Ribavirin, Peg-Interferon alpha-2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quadritherapy from Day 0 to Week 24</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asunaprevir</intervention_name>
    <description>Asunaprevir 100 mg, 1 capsule twice a day from Day 0 to Week 24</description>
    <arm_group_label>Asunaprevir, Daclatasvir, Ribavirin, Peg-Interferon alpha-2a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir</intervention_name>
    <description>Daclatasvir 60 mg, 1 tablet once a day from Day 0 to Week 24</description>
    <arm_group_label>Asunaprevir, Daclatasvir, Ribavirin, Peg-Interferon alpha-2a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Ribavirin tablets or capsules 200 mg, weight-based daily dose ( &lt;75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), from Day 0 to Week 24</description>
    <arm_group_label>Asunaprevir, Daclatasvir, Ribavirin, Peg-Interferon alpha-2a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Interferon alpha-2a</intervention_name>
    <description>Pegylated Interferon alpha-2a, by subcutaneous injection 180µg / week, from Day 0 to Week 24</description>
    <arm_group_label>Asunaprevir, Daclatasvir, Ribavirin, Peg-Interferon alpha-2a</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult ≥18 years&#xD;
&#xD;
          -  Infection with HCV genotype 4, confirmed by detectable HCV RNA ≥ 1000 IU/ml at&#xD;
             pre-inclusion&#xD;
&#xD;
          -  Non-responders to a prior treatment with pegylated Interferon and Ribavirin, with&#xD;
             non-response being defined as follows:&#xD;
&#xD;
               -  Null-response: reduction of less than 2 log10 IU/ml of HCV viral load between D0&#xD;
                  of the treatment and week 12&#xD;
&#xD;
               -  Partial response: reduction of at least 2 log10 IU/ml of HCV viral load between&#xD;
                  D0 of the treatment and week 12 but detectable HCV RNA at week 12 and week 24 and&#xD;
                  without an undetectable viral load by the end of treatment&#xD;
&#xD;
          -  Anti-HCV treatment discontinued for at least the last 3 months&#xD;
&#xD;
          -  Fibrosis at any stage, with documentation of the presence or absence of cirrhosis at&#xD;
             the pre-inclusion visit:&#xD;
&#xD;
               -  history of liver biopsy showing cirrhosis lesions (METAVIR F4), at any time in&#xD;
                  the patient's history, and/or&#xD;
&#xD;
               -  good quality (length ≥ 15 mm and ≥ 6 portal spaces) liver puncture biopsy from&#xD;
                  less than 18 months to establish the METAVIR, and/or&#xD;
&#xD;
               -  hepatic impulse elastometry (Fibroscan®) from less than 6 months and of good&#xD;
                  quality (at least 10 measurements on an incidence with an IQR of less than 30% of&#xD;
                  the mean elastometry measured and a success rate of 60%)&#xD;
&#xD;
          -  Body weight ≥ 40 kg and ≤125 kg&#xD;
&#xD;
          -  Men and women of child-bearing age and their heterosexual partners must use two&#xD;
             adequate contraceptions from 1 month before initiation of treatment up to 7 months&#xD;
             after the end of treatment for men and up to 4 months after treatment for women.&#xD;
&#xD;
          -  Written informed consents (2) signed by the patient and the investigator (on the day&#xD;
             of the pre-inclusion at the latest and before any examination required by the study)&#xD;
&#xD;
          -  Patients with Health insurance (Sécurité Sociale or Couverture Médicale Universelle)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CHILD B or C cirrhosis or a history of decompensated cirrhosis. If Child A cirrhosis,&#xD;
             presence of varices presenting an hemorrhagic risk (grade II with red spots or grade&#xD;
             III) on a fibroscopy dating from less than 3 years&#xD;
&#xD;
          -  Previous HCV therapy including HCV NS3 protease inhibitor, and/or HCV NS5A replication&#xD;
             complex inhibitor and/or HCV NS5B polymerase inhibitor&#xD;
&#xD;
          -  Positive HBs Antigen&#xD;
&#xD;
          -  Confirmed HIV-1 or HIV-2 infection&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Severe heart or lung disease&#xD;
&#xD;
          -  Transplant recipient&#xD;
&#xD;
          -  Uncontrolled dysthyroidism&#xD;
&#xD;
          -  Uncontrolled diabetes&#xD;
&#xD;
          -  Any evolutive ongoing malignant disease, including hepatocellular carcinoma, which&#xD;
             will be specifically screened for before inclusion&#xD;
&#xD;
          -  Consumption of alcohol which, in the opinion of the investigator, will be an obstacle&#xD;
             to participation of the patient and to his remaining in the study&#xD;
&#xD;
          -  Drug addiction which, in the the investigator's opinion, will be an obstacle to the&#xD;
             patient's participation and to his or her remaining in the study. Patients included in&#xD;
             a programme of substitution with methadone or buprenorphine could be included. The&#xD;
             opinion of a consultant in addictology is recommended for patients presenting with&#xD;
             current drug use or drug use in the past year.&#xD;
&#xD;
          -  Patients taking part in another clinical trial during the 30 days preceding inclusion.&#xD;
&#xD;
          -  Patient under guardianship, trusteeship or judicial protection&#xD;
&#xD;
          -  Hb &lt; 110 g/L&#xD;
&#xD;
          -  Platelets &lt; 80 000/mm3&#xD;
&#xD;
          -  Polynuclear neutrophils &lt; 1000 /mm3 (for European patients) and &lt; 750 /mm3 (for&#xD;
             African patients)&#xD;
&#xD;
          -  Kidney failure defined by creatinine clearance &lt; 50mL/mn (MDRD formula)&#xD;
&#xD;
          -  Contra-indication for treatment with Ribavirin including a history of hypersensitivity&#xD;
             to Ribavirin or to one of the excipients&#xD;
&#xD;
          -  Contra-indication for treatment with Daclatasvir or Asunaprevir including a history of&#xD;
             hypersensitivity to one of the excipients&#xD;
&#xD;
          -  Contra-indication to treatment with Interferon including psychiatric&#xD;
             contra-indications. A psychiatrist's opinion is compulsory in the following situations&#xD;
             :&#xD;
&#xD;
               -  history of psychiatric disorders requiring hospitalisation of the patient or a&#xD;
                  consultation with a specialist&#xD;
&#xD;
               -  treatment with mood stabilizers or antipsychotics during the previous year&#xD;
&#xD;
               -  history of psychiatric disorders during prior treatment with Interferon alpha&#xD;
&#xD;
               -  evidence of depression episodes, a risk of suicide, bipolar disorder and/or&#xD;
                  current behavioral disorders. These patients can only be included after a&#xD;
                  psychiatric evaluation that specifically authorizes the use of Interferon.&#xD;
&#xD;
          -  History of previous HCV treatment premature cessation (in the first 6 months) for&#xD;
             toxicity. Premature cessation for anemia or neutropenia will be authorized in the&#xD;
             absence of the use of erythropoietin or polynuclear neutrophil growth factor,&#xD;
             respectively.&#xD;
&#xD;
          -  Patients with a non-compliance history, who will be at risk of not complying with the&#xD;
             study follow-up timetable&#xD;
&#xD;
          -  Associated treatment likely to interfere with the study drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique ROULOT, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bobigny University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric BELLISSANT, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital AVICENNE</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Verdier</name>
      <address>
        <city>Bondy</city>
        <zip>93140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Haut Lévêque</name>
      <address>
        <city>Bordeaux Pessac</city>
        <zip>33601</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Albert Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondation Hôpital Saint Joseph</name>
      <address>
        <city>Marseille</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Brabois</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de l'Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de l'Archet</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de La Source</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Arnault Tzank</name>
      <address>
        <city>Saint Laurent du Var</city>
        <zip>06721</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>March 31, 2014</study_first_submitted>
  <study_first_submitted_qc>April 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2014</study_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <keyword>HCV infection</keyword>
  <keyword>HCV genotype 4</keyword>
  <keyword>Non-responders HCV infected patients</keyword>
  <keyword>Asunaprevir</keyword>
  <keyword>Daclatasvir</keyword>
  <keyword>Pegylated Interferon</keyword>
  <keyword>Ribavirin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Asunaprevir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

